You are in: eMedicine Specialties > Neurology > Neuro-imaging PET Scanning in Autism Spectrum DisordersArticle Last Updated: Nov 4, 2008AUTHOR AND EDITOR INFORMATIONSection 1 of 12
 
Author: James Robert Brasic, MD, MPH, Research Associate, Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine James Robert Brasic is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Academy of Neurology, and Movement Disorders Society Coauthor(s): Dean Wong, MD, PhD, Vice Chair of Research, Professor, Departments of Radiology, Psychiatry, and Environmental Sciences, Johns Hopkins University Oncology Center Editors: Sydney Louis, MD, Emeritus Professor, Department of Neurology, Brown University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Kenneth J Mack, MD, PhD, Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic; Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital; Amy Kao, MD, Assistant Professor, Department of Neurology, Department of Pediatrics, Division of Pediatrics, Oregon Health and Science University; Consulting Staff, Shriners Hospital Author and Editor Disclosure Synonyms and related keywords: autistic disorder, positron emission tomography, PET, Asperger disorder, Rett disorder, childhood disintegrative disorder, pervasive developmental disorders, autism, tuberous sclerosis, serotonin abnormalities, electroencephalogram, neurometric electrophysiological evaluation, Asperger syndrome, autism spectrum disorders INTRODUCTIONSection 2 of 12
 
This article addresses the body of research concerning autism spectrum disorders and other pervasive developmental disorders. While positron emission tomography (PET) scanning has contributed to the knowledge about autism spectrum disorders, the procedures described in this article are research protocols. PET scanning and other nuclear medical procedures are not indicated in the diagnosis and treatment of autism spectrum disorders and other pervasive developmental disorders. Currently, PET scanning and other nuclear medical procedures are not indicated for the evaluation of individuals who may have autism spectrum disorders and other pervasive developmental disorders. Exposure to toxins, poisons, residues, and other contaminants is one of the mechanisms hypothesized to cause autism and related conditions. While evidence exists that toxic exposure may play a role in isolated cases of autism, no convincing evidence that toxic exposure is instrumental in the causation of autism in the population in general has been reported. In particular, anecdotal reports that autism developed in children who received immunization to measles, mumps, and rubella have not been confirmed in the general population. Thus, immunization is not associated with the development of autism in general. For this reason, routine immunizations, including immunization for measles, mumps, and rubella, are recommended for the general population. Autism spectrum disorders include autistic disorder, Asperger disorder, Rett disorder, childhood disintegrative disorder, and other pervasive developmental disorders. For additional information about autistic disorder, please refer to the article Pervasive Developmental Disorder: Autism in the Pediatrics journal. For additional information about Asperger syndrome, please refer to the article Pervasive Developmental Disorder: Asperger Syndrome in the Pediatrics journal. Autism spectrum disorders include pervasive developmental disorders not otherwise specified. Thus, autism spectrum disorders include autistic disorder as well as conditions with some features of autistic disorder and without all criteria required for autistic disorder. Autistic disorder is probably a heterogeneous condition with multiple causes, some of which are unknown. A major concern in the interpretation of reports about positron emission tomography (PET) scans in autism spectrum disorders is the accuracy and the precision of the diagnoses. The widely used systems of nomenclature, including the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)1 and the International Classification of Diseases, Ninth Revision, Clinical Modification, Fourth Edition (ICD-9-CM)2 list criteria for several autism spectrum disorders. While both DSM-IV-TR and ICD-9-CM contain criteria for various autism spectrum disorders, those criteria are listed in an outline fashion that challenges inexperienced readers. Those who are expert in autism spectrum disorders know what the terms of DSM-IV-TR and ICD-9-CM mean. On the other hand, the sketchy descriptions of both DSM-IV-TR and ICD-9-CM are prone to misinterpretation by inexperienced readers. Therefore, attempts by inexperienced individuals to diagnose autism spectrum disorders by the application of criteria from DSM-IV-TR and ICD-9-CM are fraught with error. Specialized diagnostic procedures have been developed for autistic disorder and other autism spectrum disorders. The diagnostic tools for autism spectrum disorders require training in order to attain a reliable administration. The detailed description of the procedures to diagnosis autistic disorder and other autism spectrum disorders is beyond the scope of this article. Please refer to the articles Pervasive Developmental Disorder: Autism and Pervasive Developmental Disorder: Asperger Syndrome in the Pediatrics journal for suggestions about screening for these conditions in clinical and research settings. When in doubt about the possible presence of autism spectrum disorders, please refer the individual to a clinician experienced in the diagnosis of autism spectrum disorders for a definitive evaluation. Clinical symptoms of autism spectrum disorders include problems with social interaction, problems in making friends, and limited nonverbal communication. Since social deficits are a hallmark of autism spectrum disorders, researchers are investigating the nature of nonverbal communications, including facial recognition and interpretation of affect exhibited by facial expressions. The understanding of hand gestures and eye gaze provides crucial clues about the feelings and intentions of others. Persons with autism spectrum disorders exhibit deficits in facial perception. Instead of identifying people on the basis of overall facial configuration, persons with autism spectrum disorders use the lower face, the mouth, and other specific portions of the face to identify others. Thus, people with autism spectrum disorders actually may identify the faces of people by focusing on the objects that form the face rather than the whole person. Megalencephaly has been reported in a few cases of autistic disorder. Thus, a subset of individuals with autistic disorder may be characterized by this finding. The cerebella of some individuals with autistic disorder demonstrate hypoplasia while others demonstrate hyperplasia. Additionally, oculomotor studies have provided evidence of neocortical dysfunction of the prefrontal cortex and connections to the parietal lobe. Separate subgroups with neocortical dysfunction and others with cerebellar dysfunction may exist. Perception is accomplished in the brain by means of a parietal pathway for spatial and motor function and a temporal pathway for identification of objects, faces, and gestures. Anomalies in the amygdala and other structures of the medial temporal lobe have been demonstrated repeatedly in autism spectrum disorders, suggesting involvement of the temporal pathway for visuoperceptual processing. Functional magnetic resonance imaging (fMRI) of people with autism spectrum disorders demonstrates reduced activation in the fusiform gyrus, the portion of the brain associated with facial recognition, and increased activation of adjacent portions of the brain associated with recognition of objects. fMRI also suggests that, in some individuals with Asperger syndrome and high-functioning autism, dysfunctional connections among limbic and paralimbic regions, the cerebellum, and the extrastriate visual cortices occur during the process of identification of the emotion expressed by faces and the gender of the face. The history of a suicide attempt is important because subjects experience both physical and psychological stress before, during, and after scans. Individuals who are acutely suicidal merit inpatient psychiatric hospitalization. Generally, subjects who are suicidal are not appropriate for scans for research purposes. (The special needs of research on suicide are beyond the scope of this article.) In order to obtain relevant screening information on all potential research subjects, we have prepared a Questionnaire for Subjects (see Image 9 for a printable version). The Questionnaire for Subjects can be sent to individuals as part of the screening process. Potential subjects for research studies can be excluded from further participation if the presence of exclusionary criteria is identified on review of the Questionnaire for Subjects. For clinical studies, the presence of positive findings on the Questionnaire for Subjects indicates the need for tailoring the future studies to the needs and limitations of the individual. After review of the Questionnaire for Subjects confirms that the person is suitable for further evaluation, then a medical history and physical examination must be accomplished before nuclear studies are performed. Structured interviews, using a Nuclear Medical History Recording Form (see Image 10 for a printable version) and examinations, using the Nuclear Medical Physical Examination Recording Form (see Image 11 for a printable version) are helpful to verify that an adequate assessment has been obtained for nuclear medical procedures. Typically, research subjects have few findings on medical history and physical examination. The presence of positive findings on medical history and physical examination indicates the need to verify the absence of exclusionary criteria for research studies. Also, the presence of positive findings on medical history and physical examination indicates the need for consideration of possible contraindications for clinical studies. The needs and limitations of each individual must be considered before proceeding with nuclear studies. Because the findings in the brains of people with autism and related conditions may be lateralized, identification of the lateral preferences of the subject is a crucial component of the examination of each subject. Denckla developed a quick procedure, suitable for clinical settings, that is used to identify the lateral preferences for the use of the eye, the hand, and the foot in children, adolescents, and adults.4 Before scans of the brain are performed, the Lateral Preferences Examination Form (see Image 12 for a printable version) is completed for all subjects to identify the preferred side for the eye, the foot, and the hand. The examiner scores the Lateral Preferences Examination in vivo. In addition to the live rating by the examiner, the Lateral Preferences Examination is videotaped for later blind rating by experts unfamiliar with the status of the subject. The blind videotape rating of the Lateral Preferences Examination is useful to determine reliability of the live ratings of the exam. Additionally, blind rating of the videotape of the Lateral Preferences Examination is useful to protect against any left-right dissociation in the examiner. Examiners may experience confusion themselves in determining the side used by the subjects for each task. Therefore, rating of videotaped assessments is a crucial component of research studies of scans of the brain. POSITRON EMISSION TOMOGRAPHYSection 3 of 12
PET is a functional imaging technique that visualizes physiological structures in relation to events, such as performance of activities and administration of chemical agents. PET is used as a tool that provides images of the brain after administration of radioligands. PET also permits mapping of receptors throughout the body. This is particularly important with regard to autism spectrum disorders because PET can identify receptors for specific neurotransmitters in vivo. Evidence exists that some groups of individuals with autism spectrum disorders have dysfunction of serotonin, dopamine, nicotine, and other neurotransmitters in portions of the CNS. PET is a tool for assessing the function of receptors for serotonin and other neurotransmitters throughout the brain. These findings are important because they provide clues to novel therapeutic interventions. PET is used in the study of other diseases as well. Other uses of PET include measurement of regional cerebral glucose metabolism. PET with 18-fluoro-2-deoxyglucose has demonstrated interictal temporal hypometabolism consistent with marked improvement after surgical treatment in patients with partial seizures with complex symptomatology. PET with 18-fluoro-deoxyglucose is also useful in identifying malignant growths in the brain, other portions of the CNS, and other parts of the body. PET WITH 18-FLUORO-2-DEOXYGLUCOSE (FDG) IN AUTISTIC DISORDERSection 4 of 12
PET has demonstrated multiple deficits in individuals with autism. No single finding has characterized all people with autism. The results have varied from individual to individual. With 18-fluoro-2-deoxyglucose (FDG), the anterior rectal gyrus has been found to be larger on the left side than the right side in some people with autistic disorder, a finding opposite to the asymmetry seen in healthy individuals. Some people with autistic disorder also exhibit increased glucose metabolic rate in the right posterior calcarine cortex and decreased glucose metabolic rate in the medial frontal region, left posterior putamen, and left medial thalamus. Simultaneous correlation of the structures on PET and MRI has established that the right anterior cingulate gyrus is smaller and metabolically less active in a small group of high-functioning adults with autism. For example, Images 1-3 were obtained approximately 30 minutes after intravenous (IV) administration of 4.15 mCi of FDG to a 10-year-old boy with autistic disorder and unspecified mental retardation using auto-attenuation with a 24-minute acquisition period. Please refer to the article Pervasive Developmental Disorder: Autism in the Pediatrics journal for further clinical information about this patient. He is illustrated in several videotape segments of that article. Image 1 demonstrates axial sections from superior to inferior; the left side of the figure corresponds to the right side of the patient. Image 2 demonstrates coronal sections from anterior to posterior; the left side of the figure corresponds to the right side of the patient. Image 3 demonstrates sagittal images of the patient from right to left. Hypometabolism, greater on the left than the right, is demonstrated in the temporal and parietal regions. This is particularly prominent in the third and fourth depictions in Image 1. These findings suggest functional bases for the abnormalities in assessing environmental visual and emotional cues. Reversal in the size of the anterior rectal gyrus and reversal of hemispheric dominance for language in some people with autistic disorder suggest possible bases for the social, emotional, and language deficits. In people with tuberous sclerosis and autistic disorder, scans with FDG demonstrate that glucose metabolism is decreased bilaterally in the lateral temporal gyri and increased bilaterally in deep cerebellar nuclei. PET WITH ALPHA-[11C]METHYL-L-TRYPTOPHAN IN AUTISMSection 5 of 12
Serotonin metabolism in autistic disorder Evidence is mounting that abnormalities of serotonin metabolism play an important role in individuals with autism spectrum disorders. Whole-blood serotonin often is elevated in children with autistic disorder and normal intelligence. Also, in boys with autistic disorder, serotonin synthesis typically is decreased in the frontal region and thalamus on one side of the brain and increased in the dentate nucleus of the opposite cerebellum. Therefore, serotonin synthesis appears to vary distinctly in subgroups of people with autistic disorder that are based on sex and intelligence. Elucidation of the role of serotonin in development and maintenance of the symptoms and signs of autistic disorder will facilitate development of treatments targeted to correct the specific deficits of each subtype, including gene transfer strategies. The fact that one third of people with autistic disorder demonstrate elevated blood serotonin levels gives reason to suspect that some people with autistic disorder or other pervasive developmental disorders may have abnormalities in the serotonergic pathways in the brain and other parts of the body. Chugani reviewed the evidence for anomalous development of the serotonin system in the brain in autism.6 Considerable evidence indicates that abnormalities in the metabolism of serotonin in the brain characterize a large group of individuals with autistic disorder. The value of clarification of the nature of the serotonergic dysfunction has been recognized; however, most prior studies have indirectly used peripheral serotonin measures (eg, blood, urine) that are not associated consistently with the diagnosis of autistic disorder. Further evidence suggests that serotonin receptors and transporters do not function properly in individuals with autism. Elucidation of anomalies in the functioning of serotonin transporters and receptors in autistic disorder will form the basis of specific therapy targeted to meet identified deficits. Evidence from multiple sources suggests that dysfunctions of serotonin receptors and transporters characterize distinct biologic classes of individuals with autism spectrum disorders. Recently, PET has been employed to suggest the function of portions of the brain associated with the deficits observed through neurophysiological and neuropsychological examination. However, quantitative interpretation of this method has not been confirmed. Alpha-[11C]methyl-L-tryptophan (AMT), a tracer for measuring the synthesis of serotonin, has been used with PET. Studies using PET after administration of AMT, primarily of children with autistic disorder, have demonstrated striking anomalies of serotonin synthesis in boys. Children with autism demonstrate several patterns of abnormal cortical development, including the left cortex and the right cortex. Left cortical AMT decreases in children with autism are associated with marked language disorders.7 Serotonin dysfunction in comorbid disorders Evidence to support the hypothesis that serotonin dysfunction causes some cases of autistic disorder comes from studies of the neurophysiology of other disorders commonly encountered in people with autistic disorder, including mood disorders, Tourette disorder, and obsessive-compulsive disorder. Dysregulation of serotonin metabolism is implicated in the pathogenesis of major depression and obsessive-compulsive disorder. The rates of depression, obsessions, and compulsions often are increased in populations of individuals with autistic disorder. Some individuals with Tourette disorder have evidence of dysfunction of transmission of dopamine and serotonin. Dysregulation of serotonin in the subthalamus has been suggested in some studies of Tourette disorder. Interaction of abnormal functions of the dopaminergic and serotonergic systems may contribute to Tourette disorder. Role of serotonin in development of affiliation and cognition Multiple aspects of growth, including affiliation and cognition, are hypothesized to depend on serotonin during development. Affiliate behaviors in animals, including humans, appear to depend on serotonin, the interaction of serotonin and opioid peptides, and the neurohypophyseal hormones oxytocin and vasopressin. Several lines of evidence in animals and humans suggest that serotonin is crucial to development and maintenance of normal affiliate behaviors. Additional evidence suggests that serotonin regulates development and function of the brain and that disrupted development of the serotonin system leads to autistic disorder and mental retardation. Adequate serotonin appears crucial early in development. Failure to experience normal social interactions in infancy and childhood may prevent development of normal socialization at later stages of life, as in rats. Thus, during a critical period in gestation, infancy, and early childhood, the presence and effects of serotonin may be crucial for development of social skills in humans. Inadequate stimulation of serotonin to portions of the human brain early in life may create abnormalities of regulation of serotonin metabolism that cannot be corrected later. Thus, dysregulation of serotonin metabolism may be permanent in the brains of people deprived of necessary serotonin influences at key stages of early development. Furthermore, facilitation of serotonin appears to promote social confidence and the ability to relate to others. Therefore, persuasive evidence indicates that serotonin exerts a key role early in life on portions of the brain necessary for development of affiliation and cognition. Peripheral serotonin abnormalities in autistic disorder Elevated levels of whole-blood serotonin consistently have characterized a group of approximately one third to two thirds of individuals with autistic disorder and their parents and siblings, despite ethnic variations. However, some samples of children with autistic disorder have demonstrated decreased serotonin uptake. The presence of a familial deficit in serotonin metabolism is suggested further by the finding that parents of autistic children who themselves (the parents) have elevated whole-blood serotonin levels also have more depression, obsessions, and compulsions. The recent demonstration of hyperserotonemia in children with autistic disorder without mental retardation and hyposerotonemia in children with mental retardation without autistic disorder raises the possibility that peripheral serotonin levels in autistic disorder may vary according to levels of intelligence of the subjects. This finding suggests that children with autistic disorder with mental retardation may be biologically distinct, in terms of dysfunction of the serotonin system, from children with autistic disorder without mental retardation. Reduction of serum tryptophan to large neutral amino acid ratios characterizes a group of children with autistic disorder, suggesting decreased availability of brain tryptophan, which is a precursor of serotonin. A tripeptide that stimulates uptake of serotonin into platelets has been demonstrated in the urine of almost two thirds of a sample of children with autism. Decreased central serotonin binding due to antibodies to central serotonin (5-HT1A) receptors and decreased central serotonergic response have been proposed as mechanisms that mediate hyperserotonemia in some individuals with autistic disorder. However, autoantibodies against 5-HT1A receptors were not demonstrated in a small group of children with autism. General serotonin receptor binding, without determination of serotonin receptor subtype, is inhibited by the plasma of children with autistic disorder without mental retardation but is not inhibited by the plasma of children with mental retardation without autistic disorder or by the plasma of children with typical development. These findings are apparently due to the presence of blocking antibodies and not to high plasma concentrations of serotonin. Therefore, serotonin may trigger a B-cell–mediated autoantibody response to the serotonin receptor in children with autistic disorder. The contribution of antiserotonin receptor antibodies to the symptomatology of autistic disorder is suggested by the motor inhibition seen in mice treated with antiserotonin antibodies. Although several studies have used the resemblance of serotonin type 2A receptors in human platelets and in the human frontal cortex to indirectly infer the existence of dysfunction of frontal cortical serotonin 2A receptors from the elevations of whole-blood serotonin levels in groups of people with autistic disorder, a recent study assessing serotonin type 2A receptors in the platelets and the brains of the same individuals found no correlation. When using PET after administration of [18F]setoperone to measure central serotonin type 2A receptors and [3H]lysergic acid diethylamide to measure serotonin type 2A receptors on the platelets of 12 healthy volunteers, no correlation between binding potentials was found in any one individual. These recent results challenge the assumption that peripheral platelet serotonin type 2A receptors can be used to represent those in the brains of living human beings. Positron emission tomography studies Impairment of dentatothalamocortical pathways has been indicated in people with autism by use of PET after administration of AMT. Seven boys and one girl with autistic disorder and 5 of their nonautistic siblings were studied after administration of AMT. Asymmetries were observed in all boys with autistic disorder but not in the girl with autistic disorder. Five boys with autistic disorder demonstrated decreased serotonin synthesis in the left frontal cortex and the left thalamus and increased serotonin synthesis in the dentate nucleus of the right cerebellum. The other 2 boys with autistic disorder demonstrated decreased serotonin synthesis in the right frontal cortex and the right thalamus and increased serotonin synthesis in the dentate nucleus of the left cerebellum. In contrast with their 5 nonautistic siblings, the 7 boys with autistic disorder demonstrated statistically significant asymmetry indices for the frontal cortex, the thalamus, and the dentate nucleus combined and separately for the frontal cortex and the thalamus. A subsequent study of PET after administration of AMT to 9 girls with autistic disorder revealed asymmetry of frontal cortical synthesis in the 4 girls without mental retardation but not in the 5 girls with mental retardation (P = .003). Heterogeneous cerebellar anomalies were observed in 3 of the 4 girls with frontal asymmetries. These studies suggest that girls with autistic disorder without mental retardation may exhibit dysregulation of serotonin metabolism similar to boys with autistic disorder, while girls with autistic disorder with mental retardation may have different frontal serotonin metabolism. Thus, PET studies of serotonin synthesis in autistic disorder suggest that serotonin metabolism in autistic disorder varies biologically according to sex and intelligence. A subsequent study using AMT confirmed the earlier findings of atypical serotonin synthesis in children, adolescents, and adults with autistic disorder. Thirty children with autistic disorder, 8 of their siblings, and 16 children with epilepsy were evaluated after administration of AMT. This sample included the 8 children with autistic disorder and their 5 siblings described in the previous paragraph. Children aged 2-5 years with typical development exhibited higher serotonin synthesis than that exhibited by adults; as children grow, the serotonin synthesis gradually declines to adult values. The decline to adult values occurs earlier in girls than in boys. In contrast, boys, but not girls, with autistic disorder exhibit decreased focal serotonin synthesis in the frontal cortex and thalamus at all ages. Chandana and colleagues used AMT to study 117 children with autism to find groups with left cortical abnormalities, with right cortical abnormalities, and without abnormal cortical asymmetries.7 Children with left cortical AMT decreases showed severe language impairments. Children with right cortical AMT decreases showed more left and mixed handedness. Whole-brain serotonin synthesis is decreased in both boys and girls with autistic disorder as compared to children with typical development, and it gradually increases with age to values 1.5 times greater than those of adults with typical development. In adults with typical development, serotonin synthesis is higher in women than in men. However, inaccuracies are likely because of the failure to employ partial volume corrections to compensate for ventricular enlargement and atrophy or inadequate development reported in the corpus callosum, cerebellum, temporal lobes, and parietal lobes of some individuals with autistic disorder. The partial volume correction is likely to be important because of the unreliability of manually outlining portions of MRIs. Treatment studies with serotonergic agents Dysfunction of central serotonin receptors and transmitters in some individuals with autistic disorder, possibly through interactions with central glutamate pathways, is suggested by reports of beneficial effects of medications that increase central serotonin, such as 5-HT2A receptor antagonists. However, treatment with serotonergic agents is not consistently beneficial for serious symptoms of autistic disorder, such as self-injury. The symptom provocation strategy of acute depletion of brain serotonin induced by a tryptophan-poor amino-acid load worsened symptoms in a group of adults with autistic disorder, possibly by reducing serotonin levels in the brain. Hypersensitivity of serotonin type 1D receptor in autistic disorder is suggested by the greater growth hormone response and increase of repetitive behavior of a small sample of adults with autistic disorder treated with sumatriptan, a serotonin type 1D agonist, as compared to placebo. Furthermore, development of serotonin transporter regulatory agents may result in new therapies targeted at specific deficits of serotonin metabolism of a group of people with autism. Serotonin in sleep abnormalities of autistic disorder Additional evidence pointing to dysregulation of serotonin metabolism in autistic disorder includes the likely pathophysiology of the sleep abnormalities in people with autistic disorder. Genetic evidence for serotonin anomalies in autistic disorder A strong genetic etiology probably exists for many cases of autistic disorder. Genetic studies provide evidence for the association between serotonin transporter and autistic disorder. A study of a German sample of people with autism spectrum disorders revealed higher frequency and preferential transmission of the long allele of a common polymorphism, the serotonin transmitter gene-linked polymorphism region, in the upstream regulatory region of the serotonin transporter. However, another study with an international sample of subjects demonstrated no association of the serotonin transporter gene and autistic disorder. Another study did not confirm the association of the serotonin type 7 receptor with autistic disorder. Ethnic differences in study populations may account for some of the discrepancies between study results. Use of PET after administration of AMT facilitates identification of alterations in metabolism of serotonin in the brains of persons with autistic disorder and related conditions. Gross abnormalities have been detected by visual inspection of PET scans of boys with autistic disorder after administration of AMT. Most boys with autistic disorder display decreased accumulation of AMT in the left frontal cortex and left thalamus and elevated accumulation of AMT in the right dentate nucleus of the cerebellum. A minority of boys with autistic disorder display a pattern of accumulation of AMT that is the mirror image of the pattern seen in the majority of boys with autistic disorder, ie, they have decreased accumulation of AMT in the right frontal cortex and the right thalamus and elevated accumulation of AMT in the left dentate nucleus of the cerebellum. In addition, the brother of a boy with autistic disorder was a calendar calculator who lined up his toys ritualistically and demonstrated increased accumulation of AMT in the right dentate nucleus of the cerebellum. Since deficits of the frontal lobes often are manifested by problems in executive functioning, these findings suggest a physiological basis for the problems of interpreting and initiating social interactions. In addition, anomalous thalamic findings indicate a functional source for the problems with analyzing environmental stimuli and performing appropriate responses. The anomalies in the dentate nucleus may provide the explanation for the clumsiness and other coordination problems of some boys with autistic disorder. Furthermore, the findings suggest a deficiency in the pathway connecting the affected frontal lobe with the ipsilateral thalamus and the contralateral cerebellum. Thus, altered serotonergic metabolism in the dentatothalamocortical pathways may be a pathophysiological mechanism of autistic disorder in some boys. In people with tuberous sclerosis and autistic disorder, scans with AMT demonstrate increased uptake bilaterally in the caudate nuclei. PET WITH A DOPAMINE TRANSPORTER PROBE IN RETT DISORDERSection 6 of 12
The dopamine transporter ligand beta-carbomethoxy-3 beta-4-fluorophenyl tropane (CFT) has been used to study patients with Rett disorder and healthy control subjects. Patients with Rett disorder demonstrate reduction in the binding potential of CFT in the caudate and the putamen. While one group of researchers using PET after administration of N-(11C) methylspiperone (NMS) found low normal values of receptor density of postsynaptic D2-like dopamine receptors in the caudate of subjects with Rett disorder, other researchers using single-photon emission computed tomography (SPECT) after administration of iodolisuride I 123 found increased specific binding of this radiotracer to the D2-like dopamine receptor in subjects with Rett disorder. These results suggest dysfunction in dopamine transport in the caudate and putamen of people with Rett disorder. These findings provide a basis for explaining the abnormal movements and postures observed in these subjects. The discrepancies among the groups suggest that Rett disorder has heterogeneous causes and manifestations. Increased and decreased dopamine-receptor binding may characterize different classes of subjects with Rett disorder. Alternatively, dopamine receptor binding may change at different stages in the progression of Rett syndrome. Another explanation is that different findings may result from the specific protocols, including radiotracers, used by the research groups. OTHER PET STUDIESSection 7 of 12
Regional cerebral blood flow (rCBF), dopamine synthesis rate, and dopamine D2 receptor binding were assessed in 6 children aged 3-5 years utilizing [15O] water (12 MBq/kg), L-(11C)DOPA (6 MBq/kg), and NMS (4 MBq/kg), respectively. The children were treated with 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (RBH4), a cofactor for tyrosine hydroxylase in the biosynthetic pathway of catecholamines and dopamine, at a dose of 3 mg/kg/day with twice-daily oral administrations for 12 weeks in an open fashion. The rCBF did not differ from that of adults. L-(11C) DOPA utilization rate and NMS binding were elevated in all subjects before treatment with RBH4. After treatment, NMS binding in the caudate was reduced by 10%, and that in the putamen was reduced by 8%. The L-(11C) DOPA utilization rate remained unchanged. The increased dopamine D2 receptor binding seen before treatment was reduced by the therapy. PET scans after IV administration of 25 mCi of [15O] water as a slow bolus over 20 seconds revealed reversal of hemispheric dominance during verbal auditory stimulation, reduced auditory dominance activation during verbal auditory stimulation, and reduced cerebellar activation during nonverbal auditory perception in adults with high-functioning autistic disorder, suggesting cerebellar dysfunction and atypical dominance for language. PET scans after IV bolus administration of 0.5 or 7 mCi of [15O] water revealed hypoperfusion in the left, right, or both temporal lobes in children with autistic disorder. PET scans after IV bolus administration of 300 MBq of [15O] water revealed increasing rCBF (1) in the medial prefrontal cortex with increasing horizontal gaze aversion and (2) in the superior and medial temporal gyri with increasing direct gaze in a group of healthy women. This finding is relevant to the understanding of autism spectrum disorders because gaze is hypothesized to reflect the ability to detect the mental states of others. People with high-functioning autism, Asperger syndrome, and related autistic spectrum disorders frequently demonstrate impaired ability to comprehend the mental states of others. The ability to understand the mental states of others has been termed the ability to formulate a theory of mind. The deficits in formulating a theory of mind for others have been further investigated by PET scans after IV bolus administration of [15O] water to adults with high-functioning autism or Asperger syndrome and to healthy volunteers while watching aminated sequences. While both groups identified random and goal-directed movements, the subjects with high-functioning autism or Asperger syndrome displayed impaired ability to interpret interactions among moving figures with implied intentions. PET scans during the animations with implied intentions demonstrated more activation in the medial prefrontal cortex, the superior temporal sulcus at the temporoparietal junction, and the temporal poles in the healthy adult volunteers than in the subjects with high-functioning autism or Asperger syndrome. While increased activation in the extrastriate region was present in both groups during the animations with implied intentions, people with high-functioning autism or Asperger syndrome had reduced functional connectivity between the extrastriate region and the superior temporal sulcus at the temporoparietal junction. These results suggest a neuroanatomical hypothesis for the impaired ability of people with high-functioning autism and Asperger syndrome to recognize the mental states of others. BRAIN SCANS IN AUTISM DISORDERSection 8 of 12
The rCBF is estimated by radioisotope brain imaging. Hexamethylpropyleneamine oxide (HMPAO), a lipophilic agent, typically is labeled with technetium Tc 99m. Deficits have been demonstrated in individuals with autistic disorder; however, no anomaly has been found consistently. Some people with autistic disorder have exhibited reduced rCBF in the vermis, cerebellar hemisphere, thalami, basal ganglia, and parietal and temporal lobes. These abnormalities may be clarified by future studies to identify biological subgroups. MULTIMODAL IMAGING IN AUTISTIC DISORDERSection 9 of 12
While PET scans are useful to identify regional cerebral metabolism and the distribution of neuroreceptors, they do not provide a comprehensive picture of cerebral functioning in people with autism spectrum disorders. For a thorough evaluation, multimodal imaging, ie, assessment of cerebral function through nuclear, radiological, electrophysiological, and other techniques simultaneously, is helpful. PET and radiological imaging A practical example of multimodal imaging is the use of a radiological procedure, such as MRI or CT, and PET. MRI and CT are optimal tools to identify the anatomic structures of the brain, while PET is a good way to identify the physiology of the brain. The findings may be compared by having the subject wear a face mask with fiducial markers during both the MRI or CT scan and the PET. The mask allows subsequent coregistration of the MRI or CT scan and the PET and thus superimposition the anatomic and physiological images. Coregistration is a time-consuming procedure, and error may be introduced in the attempt to superimpose images that are not identical. The newly developed PET-CT resolves the problem of coregistration by simultaneously producing both images. PET and electrophysiological imaging Another type of multimodal imaging is the use of psychophysiological and electrophysiological measures in conjunction with PET. For example, a neurometric evaluation includes electroencephalography, visual evoked potentials, cortical auditory evoked potentials, auditory cognitive evoked potentials, and somatosensory evoked potentials. The neurometric protocol can be performed after PET evaluation to provide a view of the electrical activity of the different portions of the brain along with the physiological assessment provided by PET. For example, the boy with autism and unspecified mental retardation illustrated by PET scans in images 1, 2, and 3 was evaluated by a neurometric battery also. When he was aged 8 years, an electrophysiological protocol was obtained. Image 4 illustrates a page of the electroencephalogram, which demonstrates predominant theta activity. Alpha activity predominates in the posterior regions and the vertex. No paroxysmal events are noted. Shortly before his fourteenth birthday, he developed nocturnal seizures. Image 5 illustrates the neurometric quantitative electroencephalogram of this subject. The first row demonstrates diffuse low absolute power in all leads in all bands, reaching significance at the P <.05 level for delta activity on the left side at central, parietal, and posterior temporal regions. The second row demonstrates the relative power. Nonsignificant diffuse excess of theta can be observed on the anterior regions of the left hemisphere (second row). Deficits of theta and delta and an excess of alpha at the vertex, also in the second row, are significant (P <.01). The interhemispheric power asymmetry illustrated in the third row is normal. The fourth row illustrates an extremely abnormal (P <.01) bipolar frontal-temporal hypocoherence in beta activity. The interhemispheric coherence is otherwise normal (fourth row). Image 6 illustrates a normal left brainstem auditory evoked potential. Image 7 illustrates a normal right brainstem auditory evoked potential. Image 8 illustrates normal auditory cognitive evoked potentials recorded in response to common and rare tones (P300). Images 4 -8 illustrate a slightly abnormal neurometric electrophysiological evaluation similar to some children with learning disabilities (P <.05). Images 4-8 were provided through the courtesy of E. Roy John, PhD, Neurometrician, Brain Research Laboratories, Department of Psychiatry, Bellevue Hospital Center and the New York University School of Medicine, New York, New York. Thus, multimodal imaging of PET and neurometric electrophysiological evaluations are helpful to obtain an overall view of brain metabolism and physiology. ACKNOWLEDGMENTSSection 10 of 12
This research is supported by the Essel Foundation; the National Alliance for Research on Schizophrenia and Depression (NARSAD); the Tourette Syndrome Association, Inc; the National Institutes of Health; the Department of Psychiatry of Bellevue Hospital Center; and the New York University School of Medicine, New York, New York. The cooperation of the Health and Hospitals Corporation of the City of New York is gratefully acknowledged. MULTIMEDIASection 11 of 12
REFERENCESSection 12 of 12
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View Full Size Image
